Education
About Us
Working with TipRanks
Follow Us
MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
MBX Stock Chart & Stats
$40.91
-$0.30(-2.05%)
At close: 4:00 PM EST
$40.91
-$0.30(-2.05%)
Day’s Range― - ―
52-Week Range$4.81 - $44.89
Previous CloseN/A
Volume52.29K
Average Volume (3M)774.64K
Market Cap
$1.93B
Enterprise Value$207.43M
Total Cash (Recent Filing)$391.67M
Total Debt (Recent Filing)$623.00K
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Mar 23, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding44,902,300
10 Day Avg. Volume596,644
30 Day Avg. Volume774,642
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.39
Price to Sales (P/S)0.00
P/FCF Ratio-11.08
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.35
Forecast
1Y Price Target
$61.16Price Target Upside49.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.12
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DataStrong Phase II hypoparathyroidism results increase confidence in Phase III success and support a best-in-class profile that could expand the therapy's commercial opportunity.
Dosing Convenience And Market AdoptionOnce-weekly dosing shown in trials is expected to be preferred by many physicians and patients, potentially expanding the hypoparathyroidism market and converting users from daily injectables.
Platform TechnologyProprietary peptide prodrug chemistry produces extended half-life and infusion-like pharmacokinetics, appearing well suited to reduce gastrointestinal toxicity and improve the program's risk/benefit profile.
Bears Say
Clinical And Regulatory RiskConcerns about durability of response and the potential for unexpected safety findings raise the risk of late-stage trial setbacks or regulatory delays that could hinder approval timelines.
Funding And Dilution RiskSignificant development costs create a cash need that could lead to equity issuance and dilution, which may pressure the share price if additional financing becomes necessary.
Safety ConcernsHigher-dose groups experienced more frequent hypercalcemia during titration, indicating a safety issue that could necessitate dose modifications or affect clinical adoption.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $4.81 and its highest was $44.89 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $1.93B.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is Mar 23, 2026 which is in 66 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.062.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.65.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 44,902,300 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went up 9.712%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MBX Biosciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.16 (49.50% Upside)
$61.16 (49.50% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 124.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $537.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
257.05%
12-Months-Change
Fundamentals
Return on Equity
-24.43%
Trailing 12-Months
Asset Growth
41.67%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Stock 12 Month Forecast
Average Price Target
$61.16
▲(49.50% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
Currently, No data available
---